Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 19

    1.

    Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease.

    Sharma A, Szeto K, Desilets AR.

    Ann Pharmacother. 2012 Feb;46(2):248-54. Epub 2012 Jan 10. Review.

    PMID:
    22234991
    [PubMed - indexed for MEDLINE]
    2.

    Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk.

    Gan-Or Z, Bar-Shira A, Dahary D, Mirelman A, Kedmi M, Gurevich T, Giladi N, Orr-Urtreger A.

    Arch Neurol. 2012 Jan;69(1):105-10.

    PMID:
    22232350
    [PubMed - indexed for MEDLINE]
    3.

    Microtubule affinity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: effects on mitochondrial transport.

    Matenia D, Hempp C, Timm T, Eikhof A, Mandelkow EM.

    J Biol Chem. 2012 Mar 9;287(11):8174-86. Epub 2012 Jan 11.

    PMID:
    22238344
    [PubMed - indexed for MEDLINE]
    4.

    Development of Parkinson's disease in patients with Narcolepsy.

    Christine CW, Marks WJ Jr, Ostrem JL.

    J Neural Transm. 2012 Jun;119(6):697-9. Epub 2012 Jan 10.

    PMID:
    22231845
    [PubMed - in process]
    5.

    Changes of hand preference in Parkinson's disease.

    Stochl J, Croudace TJ, Brožová H, Klempíř J, Roth J, Růžička E.

    J Neural Transm. 2012 Jun;119(6):693-6. Epub 2012 Jan 10.

    PMID:
    22231844
    [PubMed - in process]
    6.

    Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status.

    Shin J, Choi S, Lee JE, Lee HS, Sohn YH, Lee PH.

    J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):315-21. Epub 2012 Jan 6.

    PMID:
    22228726
    [PubMed - indexed for MEDLINE]
    7.

    Visual hallucinations in the differential diagnosis of parkinsonism.

    Bertram K, Williams DR.

    J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):448-52. Epub 2012 Jan 6. Review.

    PMID:
    22228724
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.

    Berthet A, Bezard E, Porras G, Fasano S, Barroso-Chinea P, Dehay B, Martinez A, Thiolat ML, Nosten-Bertrand M, Giros B, Baufreton J, Li Q, Bloch B, Martin-Negrier ML.

    J Neurosci. 2012 Jan 11;32(2):681-91.

    PMID:
    22238104
    [PubMed - indexed for MEDLINE]
    9.

    Action reprogramming in Parkinson's disease: response to prediction error is modulated by levels of dopamine.

    Galea JM, Bestmann S, Beigi M, Jahanshahi M, Rothwell JC.

    J Neurosci. 2012 Jan 11;32(2):542-50.

    PMID:
    22238089
    [PubMed - indexed for MEDLINE]
    10.

    Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

    Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K; PARS Investigators.

    Mov Disord. 2012 Mar;27(3):406-12. doi: 10.1002/mds.24892. Epub 2012 Jan 11.

    PMID:
    22237833
    [PubMed - in process]
    11.

    No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease.

    Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber SJ, Doepp F.

    Mov Disord. 2012 Mar;27(3):450-3. doi: 10.1002/mds.24070. Epub 2012 Jan 11.

    PMID:
    22237792
    [PubMed - in process]
    12.

    Apathy in Parkinson's disease: diagnostic and etiological dilemmas.

    Starkstein SE.

    Mov Disord. 2012 Feb;27(2):174-8. doi: 10.1002/mds.24061. Epub 2012 Jan 11.

    PMID:
    22237755
    [PubMed - in process]
    13.

    Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool.

    Broen MP, Braaksma MM, Patijn J, Weber WE.

    Mov Disord. 2012 Apr;27(4):480-4. doi: 10.1002/mds.24054. Epub 2012 Jan 9.

    PMID:
    22231908
    [PubMed - in process]
    14.

    Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease.

    Michelakakis H, Xiromerisiou G, Dardiotis E, Bozi M, Vassilatis D, Kountra PM, Patramani G, Moraitou M, Papadimitriou D, Stamboulis E, Stefanis L, Zintzaras E, Hadjigeorgiou GM.

    Mov Disord. 2012 Mar;27(3):400-5. doi: 10.1002/mds.24886. Epub 2012 Jan 5.

    PMID:
    22223122
    [PubMed - in process]
    15.

    Taking sides: is handedness involved in motor asymmetry of Parkinson's disease?

    Melamed E, Poewe W.

    Mov Disord. 2012 Feb;27(2):171-3. doi: 10.1002/mds.24048. Epub 2012 Jan 5. No abstract available.

    PMID:
    22223083
    [PubMed - in process]
    16.

    Animal models of the non-motor features of Parkinson's disease.

    McDowell K, Chesselet MF.

    Neurobiol Dis. 2012 Jun;46(3):597-606. Epub 2012 Jan 3.

    PMID:
    22236386
    [PubMed - in process]
    17.

    Use of viral vectors to create animal models for Parkinson's disease.

    Löw K, Aebischer P.

    Neurobiol Dis. 2011 Dec 29. [Epub ahead of print]

    PMID:
    22227451
    [PubMed - as supplied by publisher]
    18.

    Is levodopa toxic? Insights from a brain bank.

    LeWitt PA, Dubow J, Singer C.

    Neurology. 2011 Oct 11;77(15):1414-5. Epub 2011 Sep 14. No abstract available.

    PMID:
    21917780
    [PubMed - indexed for MEDLINE]
    19.

    Selective attention deficits in early and moderate stage Parkinson's disease.

    Zhou S, Chen X, Wang C, Yin C, Hu P, Wang K.

    Neurosci Lett. 2012 Feb 10;509(1):50-5. Epub 2011 Dec 31.

    PMID:
    22230890
    [PubMed - in process]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk